Seres Therapeutics Inc (MCRB) Stock Price, Quote & News

Company Profile

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline pr...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 945 9626

Website: www.serestherapeutics.com

Address:

101 Cambridgepark Drive, Cambridge, United States

HedgeAlerts Nov. 14 at 5:39 PM

Hedge Alert Live - Protect Your Portfolio Contract: $MCRB $15.00 Put · NOV 21, 2025 Exp Entry Price: $2.72 - $3.40 Exit Price Target: $4.98 Profit Margin: +83% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

panterms Nov. 14 at 4:12 PM

$MCRB we will have CDTX one day.. it went from 20 to 200 and Buy Out. Same story.. reverse split and sold. MCRB too one day b 76 plus or 120 plus .

0 · Reply

panterms Nov. 14 at 3:41 PM

$MCRB Sparta is crying again... losing pants.. see you all at 76 dollors per share . Good luck

0 · Reply

MikeyDread Nov. 14 at 3:12 PM

$MCRB well done all who played along Wall St games… they never fail to deliver pay days…

1 · Reply

Shahr_ Nov. 14 at 3:00 PM

$MCRB shorts are trapped

0 · Reply

Thewolf76 Nov. 14 at 2:58 PM

$MCRB 🤩🤩🤩🤩👀👀👀 get ready💣💣💣

0 · Reply

BioCrazy1 Nov. 14 at 2:54 PM

$MCRB They cash in tomorrow. About $68K at today's price. What did they agree to is the question.

0 · Reply

disdaniel Nov. 14 at 1:23 PM

$MCRB Were/are there incentives around a mid-November deal? *eyes calendar* or was that something I imagined?

0 · Reply

BrilbeerBarry Nov. 14 at 9:26 AM

$MCRB Anyone else interested in their SER-603 data? Also interesting value driver if they can initiate a clinical trial for that one.

1 · Reply

SenefAS Nov. 14 at 9:13 AM

Merck $MRK is nearing a deal to buy Cidara Therapeutics for 3.3B $CDTX $XBI $IBB who’s next ? Seres Therapeutics 🙃 $MCRB

0 · Reply

Seres Therapeutics, Inc. (MCRB) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 7:00 AM EST - 9 days ago

Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Oct 30, 2025, 7:00 AM EDT - 15 days ago

Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025

Oct 29, 2025, 7:00 AM EDT - 16 days ago

Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155

Oct 14, 2025, 7:00 AM EDT - 4 weeks ago

Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Sep 23, 2025, 7:00 AM EDT - 7 weeks ago

Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway

Sep 22, 2025, 12:10 PM EDT - 7 weeks ago

More companies adopt co-CEO structure

IREN KKR LEN NFLX ORCL SBET

Aug 27, 2025, 7:00 AM EDT - 2 months ago

Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference

Aug 6, 2025, 9:47 PM EDT - 3 months ago

Seres Therapeutics, Inc. (MCRB) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 7:00 AM EDT - 3 months ago

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

SANA

Jul 29, 2025, 2:09 PM EDT - 3 months ago

Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough

Jul 22, 2025, 7:01 AM EDT - 4 months ago

Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025

Jul 22, 2025, 7:00 AM EDT - 4 months ago

Seres Therapeutics Announces Leadership Transition

May 27, 2025, 7:00 AM EDT - 6 months ago

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting

May 7, 2025, 2:18 PM EDT - 6 months ago

Seres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:00 AM EDT - 6 months ago

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 29, 2025, 7:00 AM EDT - 7 months ago

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

Apr 23, 2025, 7:00 AM EDT - 7 months ago

Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

Mar 13, 2025, 11:04 AM EDT - 8 months ago

Seres Therapeutics, Inc. (MCRB) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 7:00 AM EDT - 8 months ago

Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 4, 2025, 7:00 AM EST - 9 months ago

Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025

Mar 3, 2025, 7:00 AM EST - 9 months ago

Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach

Jan 16, 2025, 7:00 AM EST - 10 months ago

Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

Jan 9, 2025, 7:00 AM EST - 11 months ago

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

Dec 16, 2024, 7:00 AM EST - 11 months ago

Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference

Nov 22, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

Nov 13, 2024, 10:28 AM EST - 1 year ago

Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024

Sep 30, 2024, 5:15 PM EDT - 1 year ago

Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A

Sep 27, 2024, 3:26 PM EDT - 1 year ago

Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé

Sep 26, 2024, 4:01 PM EDT - 1 year ago

Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30

Sep 23, 2024, 12:14 AM EDT - 1 year ago

Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference

Sep 12, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

Aug 13, 2024, 3:35 PM EDT - 1 year ago

Seres Therapeutics, Inc. (MCRB) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health Science

Jun 7, 2024, 4:00 PM EDT - 1 year ago

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023

Jun 6, 2024, 6:30 AM EDT - 1 year ago

Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science

May 11, 2024, 5:34 PM EDT - 1 year ago

Seres Therapeutics, Inc. (MCRB) Q1 2024 Earnings Call Transcript

May 8, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 6, 2024, 9:30 AM EDT - 1 year ago

Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024

Apr 9, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Apr 2, 2024, 2:10 AM EDT - 1 year ago

VKTX, JANX and these biotech stocks are surging in 2024

ARQT JANX VKTX AMLX RAPT RVNC

Mar 5, 2024, 3:33 PM EST - 1 year ago

Seres Therapeutics, Inc. (MCRB) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Feb 28, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024

Feb 27, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference

HedgeAlerts Nov. 14 at 5:39 PM

0 · Reply

panterms Nov. 14 at 4:12 PM

$MCRB we will have CDTX one day.. it went from 20 to 200 and Buy Out. Same story.. reverse split and sold. MCRB too one day b 76 plus or 120 plus .

0 · Reply

panterms Nov. 14 at 3:41 PM

$MCRB Sparta is crying again... losing pants.. see you all at 76 dollors per share . Good luck

0 · Reply

MikeyDread Nov. 14 at 3:12 PM

$MCRB well done all who played along Wall St games… they never fail to deliver pay days…

1 · Reply

Shahr_ Nov. 14 at 3:00 PM

$MCRB shorts are trapped

0 · Reply

Thewolf76 Nov. 14 at 2:58 PM

$MCRB 🤩🤩🤩🤩👀👀👀 get ready💣💣💣

0 · Reply

BioCrazy1 Nov. 14 at 2:54 PM

$MCRB They cash in tomorrow. About $68K at today's price. What did they agree to is the question.

0 · Reply

disdaniel Nov. 14 at 1:23 PM

$MCRB Were/are there incentives around a mid-November deal? *eyes calendar* or was that something I imagined?

0 · Reply

BrilbeerBarry Nov. 14 at 9:26 AM

$MCRB Anyone else interested in their SER-603 data? Also interesting value driver if they can initiate a clinical trial for that one.

1 · Reply

SenefAS Nov. 14 at 9:13 AM

Merck $MRK is nearing a deal to buy Cidara Therapeutics for 3.3B $CDTX $XBI $IBB who’s next ? Seres Therapeutics 🙃 $MCRB

0 · Reply

HedgeAlerts Nov. 14 at 6:59 AM

Hedge Alert Live - Protect Your Portfolio Contract: $MCRB $15.00 Put · NOV 21, 2025 Exp Entry Price: $2.72 - $4.20 Exit Price Target: $5.71 Profit Margin: +110% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

I_am_Sparta Nov. 14 at 5:39 AM

$MCRB Zero incoming safe.... Trash is Trash

1 · Reply

LiquidThetaOptions Nov. 14 at 5:10 AM

💎 LiquidTheta® Live Actionable Trade Asset: $MCRB Contracts: $MCRB January 15, 2027 $18 Calls Scale in: $7.20- $8.80 Scale out: $28.00-$48.00 Profit Potential : 70% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

lisaparsons Nov. 14 at 12:19 AM

$MCRB why the 5 percent dip after. Shit.

1 · Reply

Neptune187 Nov. 13 at 8:57 PM

$MCRB we still far away from what this company and shareholders deserve. We must stay positive.

1 · Reply

panterms Nov. 13 at 8:43 PM

$MCRB anyone see Sparta? Must b hiding in a basement while MCRB going to 76 dollors per share plus

0 · Reply

Lynne45 Nov. 13 at 8:14 PM

$MCRB Go figure my only green 💚 in a sea of red.... Lol 😆 hoping news soon like a buy-out

0 · Reply

Thewolf76 Nov. 13 at 5:33 PM

$MCRB This is the moment when smart money quietly positions itself, while the shorts look for any exit they can find. The bandwagon is about to leave the station ..loud, fast, and without mercy. And once it happens, it’ll be too late for the shorts. Cover your ass before it’s too late…

1 · Reply

lisaparsons Nov. 13 at 2:58 AM

$MCRB hopes and prayers needed guys and gals. This has been a long haul. Bo please !

1 · Reply

LiquidThetaOptions Nov. 12 at 10:23 PM

💎 LiquidTheta® Live Actionable Trade Asset: $MCRB Contracts: $MCRB January 15, 2027 $18 Calls Scale in: $7.20- $8.80 Scale out: $28.00-$48.00 Profit Potential : 232% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

BioCrazy1 Nov. 12 at 8:08 PM

$MCRB Shorts are not concerned by the looks of it.

1 · Reply

panterms Nov. 12 at 7:50 PM

$MCRB Sparta is running away . Loser. Catch him catch him 🤪. 76 per share coming

0 · Reply

Market Cap	144.83M
Revenue (ttm)	0.00
Net Income (ttm)	140,000.00
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	102,727
Avg Vol	166,894
Day's Range	N/A - N/A
Shares Out	9.05M
Stochastic %K	98%
Beta	0.19
Analysts	Sell
Price Target	$16.00